Media Articles Related to Visken (Pindolol)
Source: MedicineNet Chronic Obstructive Pulmonary Disease (COPD) Specialty [2013.11.25]
Title: Pulmonary Hypertension
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 11/25/2013 12:00:00 AM
Increased risk of alcohol-related hypertension in individuals who flush after drinking
Source: Alcohol / Addiction / Illegal Drugs News From Medical News Today [2013.11.21]
Excessive drinking is a known risk factor for hypertension. Drinking that results in facial flushing indicates high sensitivity or even intolerance to alcohol. A study of the relationship between drinking and these two conditions has found that drinking-related hypertension has a lower threshold value and higher risk in flushers than in non-flushers.
Some allergy suffers with hypertension may be at increased risk for severe reaction
Source: Allergy News From Medical News Today [2013.11.12]
Oral allergy syndrome sufferers that take high blood pressure medications may experience extreme facial swelling and difficulty breathing the next time they bite into a juicy apple.
In low-income urban neighborhoods the rates of diabetes, hypertension, heart disease and stroke are much higher
Source: Hypertension News From Medical News Today [2013.11.07]
There is more to the cost of living in a food desert than higher prices for the few fruits and vegetables sold nearby, according to a study by an Indiana University-Purdue University Indianapolis researcher and the Marion County Public Health Department.
Further positive Opsumit (macitentan) data in pulmonary arterial hypertension presented at CHEST 2013
Source: Hypertension News From Medical News Today [2013.10.31]
Actelion (SIX: ATLN) has announced that following the recent FDA approval and positive CHMP opinion for macitentan (Opsumit®) in pulmonary arterial hypertension (PAH), further positive data on the efficacy of macitentan from the SERAPHIN study were presented at CHEST 2013 in Chicago, USA (26-31 October 2013).
Published Studies Related to Visken (Pindolol)
Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression. [2011.07]
CONCLUSIONS: Present findings represent further evidence of the acceleration and enhancement of efficacy with pindolol administered together with SSRIs, displaying a quicker and more pronounced decrease of symptoms in patients with nonresistant major depressive disorder. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00931775. (c) Copyright 2011 Physicians Postgraduate Press, Inc.
Pindolol augmentation enhances response outcomes in first depressive episodes. [2009.07]
Effectiveness of Pindolol addition to SSRIs is still a matter of debate.
Glomerular filtration rate after tramadol, parecoxib and pindolol following anaesthesia and analgesia in comparison with morphine in dogs. [2009.01]
OBJECTIVE: To compare the effects of morphine, parecoxib, tramadol and a combination of parecoxib, tramadol and pindolol on nociceptive thresholds in awake animals and their effect on glomerular filtration rate (GFR) in dogs subjected to 30 minutes of anesthesia. ANIMALS: Eight adult mixed breed experimental dogs. STUDY DESIGN: Randomized, controlled trial... CONCLUSION: Tramadol and parecoxib (either alone or in combination) can increase nociceptive thresholds in awake dogs and have minimal effects on renal perfusion in normotensive dogs subjected to anaesthesia.
Paroxetine with pindolol augmentation: A double-blind, randomized, placebo-controlled study in depressed in-patients. [2008.02]
Pindolol, a 5-HT1A autoreceptor antagonist, given in combination with selective serotonin reuptake inhibitors (SSRIs), may enhance and/or accelerate the therapeutic efficacy of SSRIs. Fifty patients, meeting ICD-10 criteria for major depressive disorder or bipolar depression, were enrolled in our randomized, placebo-controlled, double-blind trial...
Noradrenergic activity is associated with response to pindolol in aggressive Alzheimer's disease patients. [2004.06]
Loss of noradrenergic (NE) neurones in the locus ceruleus and compensatory changes in NE activity have been described in Alzheimer's disease (AD), but have never been linked to treatment. The hypothesis of this study was that central NE responsivity would predict aggression response to treatment with a NE medication, pindolol...
Clinical Trials Related to Visken (Pindolol)
EScitalopram PIndolol ONset of Action [Recruiting]
The main purpose of this study is to determine whether the antidepressant response of
escitalopram 30mg/day or escitalopram 20mg/day + pindolol, a beta blocker, is different
(faster) compared to a standard dose of escitalopram 20mg/day.
Comparison of the Pharmacokinetics of Three Generic Medications and Their Respective Brand Preparations [Recruiting]
Generic describes a pharmaceutical product that does not have a brand name or trademark.
Generic medications should be the equivalent of brand medications. Only their price should
be different. The active ingredient of the generic medication has to be within a window of
80 to 125% of the original in the blood. There are reports that this standard is not always
followed after the medication has been on the market. Indeed, it was observed that some
patients previously stable on original medications relapsed when switched to a generic.
Several factors could account for this problem. Such problems have been reported for
Pindolol, Quetiapine, and Trazodone. Some properties of specific brands of the generics and
the original brands will be examined for these three medications. The three original
medications used in this study are the Visken, the Seroquel, and the Desyrel. The three
generics are the Teva-pindolol, the Teva-Quetiapine, and the Teva-Trazodone. They are all
available on the Canadian market by prescription.
Trial of Pindolol Augmentation in Venlafaxine Treated Patients With Major Depression [Terminated]
This study investigates the hypothesis that pindolol can accelerate the response to
antidepressants in patients with major depression treated with venlafaxine.
Evaluation of [11C]Cimbi-36 as an Agonist PET Radioligand for Imaging of 5-HT2A Receptors [Recruiting]
The serotonin 2A (5-HT2A) receptor is the most abundant excitatory serotonin (5-HT,
5-hydroxytryptamine) receptor in the human brain, and multiple positron emission tomography
(PET) studies have investigated the 5-HT2A receptors in the human brain using antagonist
radioligands. However, the currently available antagonist PET radioligands bind the total
pool of 5-HT2A receptor receptors whereas a 5-HT2A receptor agonist binds the high-affinity
subgroup of the receptors which are also G-protein coupled, and thus hypothesized to be the
functional relevant population of receptors. At the Center for Integrated Molecular Brain
Imaging (CIMBI), a novel agonist PET radioligands for brain imaging of 5-HT2A receptors was
recently validated in animals (Ettrup et al. 2011, EJNMMI). In the human brain,
[11C]Cimbi-36 was validated as a selective 5-HT2A receptor agonist PET radioligand through a
blocking study with the 5-HT2A receptor antagonist pharmaceutical ketanserin. In this
validation study, the biodistribution and kinetic modelling of [11C]Cimbi-36 binding in the
human brain was also validated. With these studies, investigators will test the most
promising of these, [11C]Cimbi-36, in clinical trials, where it will provide a novel method
for detecting dysfunction in the 5-HT system. The specific aim of this clinical trial is:
- To examine the effect of acute alterations in 5-HT levels on cerebral [11C]Cimbi-36
binding in healthy volunteers who will be PET-scanned at baseline and after pharmacological
or dietary interventions that either increase or decrease cerebral 5-HT levels.
It is hypothesized that this novel agonist radioligand will provide both a more
physiological relevant measure of the 5-HT2A receptors and also reflect levels of cerebral
5-HT in humans, more specifically:
BP will decrease after pindolol and selective serotonin reuptake inhibitor (SSRI) treatment
and increase after acute tryptophan depletion (ATD). Placebo will leave binding potential
Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris [Recruiting]
The purpose of this study is to determine if long-term vasodilatory treatment is more
effective than the standard treatment in hypertensive patients with microvascular angina